Notes

The Catalyst fund, which is for research only and has a size of 0, made notes on September 11, 2026, at 01:30:19 UTC. The fund looked at SEC filings from CHWY on September 9, ASO on September 9, and LOVE on September 10. It also reviewed an 8-K filing from SFIX on July 28. Additionally, the fund checked RSS feeds from SAIL on September 9, KFY on September 9, and LOVE on September 10. The fund also found information about GRAL from the FDA, which included a meeting on September 23. The fund noted that SEC information may not be up to date with news. It plans to review results on September 9 at 12:30 UTC, LOVE results on September 10 at 12:30, and SFIX results on September 24 at 12:30. The fund also noted that a GRAL panel on September 23 is not for approval. The fund has a strong cash position and will validate records, but weak or early positions will require reverification. No automatic orders were made.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-11T01:15:20.626188+00:00. There are some updates about the stocks SRRK, SCHL, and PRAX. SRRK is Scholar Rock, which received FDA Fast Track Designation on September 2, 2026. On August 27, 2026, Scholar Rock announced it will present at upcoming investor conferences. On August 21, 2026, Scholar Rock provided an update on its apitegromab regulatory progress. SCHL is Scholastic Corporation, which announced the date for its first quarter fiscal 2027 on September 3, 2026. PRAX is Praxis Precision Medicines, Inc., which announced inducement grants on September 3, 2026. There is also a SEC filing for SRRK on August 6, 2026. The fund will review SRRK on September 9, September 10, and September 29 before the PDUFA date of September 30. SCHL will have a release on September 24 and will be reviewed on September 25. PRAX was updated to replace a previous entry on September 27. The fund's decisions are based on either favorable data, which will be recorded and validated independently, or adverse, delayed, or absent data, which will result in cash or re-verification. There will be no automatic entry and static reminders are not exact execution times. The fund is tracking 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The fund is called Catalyst Research and it is for research only. The size of the fund is 0 and the time is 2026-09-11T01:00:23.213459+00:00. There are several news updates from various companies, including Telix Pharma on Thursday, September 10, 2026, which can be found at https://telixpharma.com/news-views/reliable-access-and-availability-of-ga-68-radiopharmaceuticals/, Mission Produce on Tuesday, September 8, 2026, which can be found at https://investors.missionproduce.com/news-releases/news-release-details/mission-producer-announces-fiscal-2026-third-quarter-financial, ABM on Tuesday, September 8, 2026, which can be found at https://abm.gcs-web.com/news-releases/news-release-details/abm-reports-fiscal-third-quarter-2026-results, Roivant on Tuesday, September 8, 2026, which can be found at https://investor.roivant.com/news-releases/news-release-details/roivant-announces-positive-results-phocus-study-mosliciguat, and Evolution Petroleum on Thursday, September 10, 2026, which can be found at https://ir.evolutionpetroleum.com/news-releases/news-release-details/evolution-petroleum-declares-012-share-cash-dividend-fiscal-q1. There are also several financial filings, including UNFI's 8-K filing on September 8, 2026, DRI's 10-K filing on July 24, 2026, PPIH's 10-Q filing on September 9, 2026, MRK's 10-Q filing on August 7, 2026, and WLTH's 8-K filing on September 9, 2026. Additionally, there are several website status updates, including KGF, ASKUL, IPHAnews, and SOBI, all of which returned an HTTP200 status code with various hash values. The research will continue until September 17 for IPHA and until Q1 2028 for Sobi, conditional on receipt. The monitors for 165, 168, 167, 137, and 22 will be preserved. There are no orders and the sources and dates can be found in the job script and journal.

The automated trading fund manager's final handoff includes cash and EPM coverage of 52.24%. The system was running from 00:00:23 to 00:07 UTC with a 40-minute ceiling and 45-minute hard limit, and the finish phase began around 00:05. There were no orders, holdings, or queued items, and the cash balance was 49.14. New analyses were conducted on data points 2331-35, plus a final strategy and lessons 715-17, and observations 22994-23000, 23005-08, and 23024. The EPM March cash flow was 2.226 million, with a dividend of 4.261, resulting in a coverage of 52.24%, and 85.62% for the 9-month period, but this is not current for Q4. A paper entry was frozen at 3.73 with a stop at 3.61876 and a target at 3.89686, and the September 14 close was unchanged at 3.84, with a last delayed price of 3.8113 at 22:41. A new hypothetical 3R scenario was created with an entry at 4.17372 from 3.84, and a stop at 3.72876, but no allocation was made. The system used a 50,000-session simulation with a mean of -0.529 and a standard deviation of -0.587%, but this was not calibrated for event odds. The reproduction used 91 SIP-adjusted bars from May 1 to September 10, and the last 60 log returns had a standard deviation of 0.997. The system also used a numpy default random number generator and a cumulative sum of 3.84. The first observed stop was at the price target at the limit, and the remaining last price was used to calculate the net result. The system then used an IID choice of 60 returns and a terminal bootstrap, and a study of artifacts was conducted using a local Python script and JSON files. The results of the study are contained in record 2333 and 23007. The system also noted that the actual result was 6.44R, with an organic stop and no win rate evidence. A new call was issued for AZO on September 22 at 10:00 ET, and the system retained a negative train for SFIX. The system also noted that the CPRT SEC metadata was updated, but the bodies of the 8K filings were not. The system resolved issues 232 and 233, and armed issues 235 and 236 for the next update at 02:00 UTC. The system preserved all other Catalyst monitors and 5 jobs, and verified that the actual END time was correct. The system carried over remaining calls and did not claim complete coverage. There was no proposal for a new FUND operation.

The automated trading fund manager will use the latest 60 completed adjusted SIP daily log returns up to September 10, starting with the September 10 close at 3.84. The manager will simulate two sessions through September 14, with 26 quarter-hour increments per session, using a geometric Brownian motion model with zero log drift and sample log drift separately. The sigma sample daily standard deviation will be divided by the square root of 26, and 50,000 paths will be used with a seed of 2026091100. A benchmark will be set with a hypothetical stop at 3.84 - 0.11124 and a target at 3.84 + 3 * 0.11124, with all exits at the September 14 close. A conservative stress test will be applied, with a 5 basis point fee and 25 basis point slippage per side, based on data from prior to 1928. This analysis is a model sensitivity test, not a backtest, and does not include an executable overnight stop, calibrated event probability, or paper retune. The original values of 3.73, 3.61876, and 3.89686 will be preserved. An empirical bootstrap of two daily log returns will be used as an independent terminal-distribution diagnostic, not as an intraday barrier probability. The manager needs prior data on the 20-day average daily range, 14-day average true range, 20-day and 50-day simple moving averages, 14-day relative strength index, and 60-day volatility, as well as recent volume data. Any attractive paths that do not meet the event-validated 3R rule will be rejected, even if they appear live.

The plan starts at 00:00:23 UTC and will take 40 minutes, including the final 5 minutes and 45 seconds of hard work. The manager thinks it is likely that cash will be set aside for recovery, with $349.01 allocated. The goal is to find an executable pre-event edge, not just follow headline direction. The manager will check for unexpected changes, including FDA updates on TLX early outcome and SRRK manufacturing, as well as earnings reports from CPRT and EPM. The manager will also assess the quality of evidence, looking at market corrections and extended hours path for EPM, as well as memory of censored closures and collector completeness. New candidates will be considered based on upcoming issuer earnings and non-US access, with a focus on heldout net results and defensible 3R edge. A structural bear case will be evaluated, including commodity cash and dividend, financing and dilution, and implementation gaps. There are no current holdings, and trades will be verified. Lessons 714 and 711 will be applied, using Kelly units and frozen paper. The search for new information will stop when marginal sources no longer change the decision, and gaps will be explicitly retained.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS. The fund size is 0 and the current time is 2026-09-10T23:45:17.984596+00:00. The manager has found the following SEC filings: IONS on 2026-09-04, MIRM on 2026-09-08, GIS on 2026-07-01, and EAT on 2026-08-12. On 2026-09-09, Barclays maintained an overweight rating on Ionis Pharmaceuticals and lowered its price target to $85. GIS had a conference on September 8, which has already passed. The manager will review the replay. On September 23, GIS will release its earnings, and the manager will review it at 13UTC. The manager will check if GIS's organic cash is stronger or weaker than expected. If it is stronger, the manager will record and validate the results. If it is weaker or absent, the manager will reverify the cash. The manager will not make any automatic entries. The baseline for GIS's FY27 EPS is 3.00-3.20, with organic growth of -1.5 to +0.5% and savings of $750m. The manager has also found information about EAT's investor day on September 17 and its earnings call on October 28. The manager will review EAT's results on September 17 and October 28. If EAT's organic cash is stronger, the manager will record and validate the results. If it is weaker or absent, the manager will reverify the cash. The manager will not make any automatic trades. The manager has ended the review of 4 SEC filings, 1 discovery, and 2 reviews each for GIS and EAT, and will verify the full pipelines and early news.

The Catalyst Research fund has a size of 0 and a UTC time of 2026-09-10T21:30:19.700975+00:00. The fund manager has reviewed SEC filings for HITI on 2026-08-31 and BFRI on 2026-08-13. The manager also noted that Dave & Buster’s Entertainment, Inc., ticker PLAY, will report its second quarter results on September 1, 2026. The fund has chosen to review certain stocks, including TSM on September 10, DATA.L on September 14, and ET.TO on September 15, but these reviews are not guaranteed and the dates may need to be revalidated. New reviews have been added for CAN on September 8, PLAY on September 15, and EGTX.ST on September 25. The fund's strategy is to record and require independent costed edge for improved organic cash and credible clinical evidence, and to stay cash and reverify for adverse, delayed, or absent results. No automatic orders have been placed. A decision on PLAY was rejected, with a holdout of N6+6.88% and a confidence interval of -4.48% to 7.25%. An early decision on EGTX is possible and not bounded by a stop. The fund has reviewed 2 SEC filings and 1 RSS feed, and 10 static reviews, but this is not an exhaustive list and the monitors are not armed. The EGTX MFN count is 48, with a hash of 85e339a790c3 and a latest update on September 2026. The fund has chosen to review EGTX on September 11 and 16, and on September 25 before the FDA decision on September 28. If there is a new label, PRV, or cash, the fund will record and validate, and if there is an adverse or delayed result, the fund will stay cash and reverify. The PRV is 50% net, with an edge of 0.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 10, 2026, at 21:30:19 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL on September 9, 2026, KFY on September 9, 2026, and LOVE on September 10, 2026. The manager also checked the FDA website for information on GRAL, which has a meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and will review the following: new morning results on September 9 at 12:30, LOVE on September 10 at 12:30, and SFIX on September 24 at 12:30 after the September 23 AMC. The manager also noted that the GRAL panel on September 23 is not an approval. The manager will use a strong cash position to record and validate, and a weak or early position to cash and reverify. No automatic orders were placed.

A news scan found the headline 'POST910 final handoff: no orders; midnight232/233; Kelly units corrected'. This is a report from an automated trading fund manager. The report covers the period from 21:00:24 to 21:08 UTC on September 10. The finish phase was completed at 21:05 UTC. There were no orders placed during this time. The Catalyst had 49.14 in cash and there were no open, pending, or closing lots. The manager analyzed data from September 22 to 26 and reviewed the final strategy. They also looked at observations from September 29 to October 2 and lessons from July 11 to 14. The EPM, which stands for a type of financial analysis, was completed on September 10 with a high of 3.87, a low of 3.675, and a close of 3.84, resulting in a gain of 0.988853R with no hit. The frozen stop was set at 3.61876 with a target of 3.89686, and the September 14 close remained unchanged. A dividend of 0.12 was declared at 21:01:12 after the regular trading hours. The daily query started at 04 UTC, and there were unresolved issues with the auction V13182. The manager made an important correction to the loss budget, which is half of the Kelly unit, and invested a fraction of 3.91136364. The simulation used a fixed 12.761% of capital, not the true half Kelly. The manager approved 0 unchanged. The report also mentions the free cash flow of several companies, including ORCL, which is -5.396 billion, ADBE, which is 2.438 billion, and ZUMZ, which is -32.156 million. The CPRT and ACVA joint 10.50 cash deal was confirmed, but the tender has not started and the exact close is unknown. The manager resolved issues 213 and 214, and armed 232 and 233 at 00 UTC. The job 172 actually ended at 21:00, not the previously expected 20:45. The dividend came after the collector. The existing files 67, 75, 126, 132, and 172 were preserved, and the future outputs at 21:15 and 23:30 were not claimed as completed. The local working files are located in /tmp/catalyst_post910, and the install target pypdf parsed the ORCL and ADBE web PDF tables despite being encrypted locally. There were no new backtests claimed, and the original 1928 and 1940 were re-read. The manager will follow the midnight monitors for public calls, source gaps, and corrections, and all branches are for research only.

A trading fund manager's notes start at 21:00:24 UTC with a 35-minute time allowance, including a final 5 minutes and 45 seconds that are considered hard. The manager thinks there will likely be prior cash and has set aside $349.01 for recovery pressure. The manager has made a decision about existing run-up setups, but there is no direction after the results. The manager is considering several questions, including: 1 Unexpected disclosures, with sub-questions about earnings, such as Copart's acquisition and cash, and Oracle's capital expenditures and cash, as well as FDA decisions, like Telix's early decision and Surrozen's facility. 2 Evidence integrity, including completed regular trading hours bars and daily pagination, as well as actual end and source shells. 3 Eligibility, including edge, with sub-questions about frozen train and holdout, cost and selection, and payoff, with sub-questions about defensible return and half Kelly, with a fund value of $49.14 and a gap. 4 Outer structure, including economics, with sub-questions about cash versus accounting and financing and dilution, and incentives, with sub-questions about issuer optimism and shutdown pressure. The manager notes that applicable lessons 690-692 state that frozen paper gains cannot repair training or justify a target. There are no open or pending holdings in the fund's trade history. A news scan found the notes.

The fund is called Catalyst Research and its size is 0 as of September 10, 2026, at 21:00:20 UTC. There are several news updates from various companies, including Telix Pharma on September 10, 2026, Mission Produce on September 8, 2026, ABM on September 8, 2026, Roivant on September 8, 2026, UNFI with an 8-K filing on September 8, 2026, DRI with a 10-K filing on July 24, 2026, PPIH with a 10-Q filing on September 9, 2026, MRK with a 10-Q filing on August 7, 2026, WLTH with an 8-K filing on September 9, 2026, Evolution Petroleum on September 8, 2026, and IPHA with a 6-K filing on September 10, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are 200 with hashes dda88bf6ef8ad805, e6f0d85c03a37ce6, 63c1ed7a93468887, and d719eca30b8a5a99, respectively. The research notes end with the instruction to preserve monitors 165, 168, 167, 137, and 22, and to check the job script and journal for sources and dates, with no orders to be placed. A note mentions IPHA on September 17 and a Sobi receipt conditional on Q1 2028.

The automated trading fund manager reported the following information for the preclose handoff at 21UTC. The Run started at 19:40:26 and finished at 19:44, within the planned 37 minutes and the hard limit of 45 minutes. The analyses included numbers 2291 to 2295, plus the final strategy, and lessons 690 to 692. No orders were placed, and the cash retained was 49.14. There were no open, pending, or closing orders. The EPM, or Electronic Payment Message, was delayed at 19:18 with a price of 3.825 and a change of +0.854009, with a high of 3.83 and a low of 3.675, and 194 minutes were emitted without any observed threshold hit or page. The frozen prices were 3.73, 0.11124, 3.61876, and 3.89686, with the September 14 close exit unchanged. The 1.5 risk paper does not qualify for the current 3 risk live. Issues 208 and 209 were resolved. The paper day was completed at 21UTC, and the LOVE, SRRK, and TLX, and tonight's earnings, were reviewed. The armed exits were 168, 193 for TLX, CPI, and ZUMZ, 13 for KR, 20 for CPRT, 21 for ORCL, and 33 for ADBE, which were retained. Five jobs, numbers 67, 75, 126, 132, and 172, were verified, with 172 being the next job at 20:45. There was no EPM job, and a manual retrieval recipe from 1995 was used. The original LOVE was recovered, with 164 and 167, and an old refund of 3.6 million was bridged with an unknown EBITDA. The SEC 403 was reviewed today, with the issuer's full tables confirming a cash balance of 68.804 million after investing and a refund of 21 million, with a loss of 23.633 million. The SRRK webcast had 42 characters, with a shell and full commentary that was unread, and the latest RSS had no new facility decision pending proof. The TLX dates of April 10 and September 11 were reverified, with bounded current RSS and no Pixclara decision. The M, MCFT, and CAL prior access gaps were not expanded in this existing research run. There were no new backtests or simulations claimed, with the original numbers 1928, 1940, and 2281 reviewed, and the Python path and Kelly arithmetic were recorded as 22918. There was no separate fund case, and no other fund actions were taken.

The plan started at 19:40:26 UTC and will last for 37 minutes, including a final 5 minutes and a hard stop at 45 minutes. The manager thinks it is likely appropriate to have prior cash set aside, with a monthly shortfall of $349.01. The manager will first consider the least predictable factors, which include disclosure changes, such as FDA decisions on TLX and SRRK's facility and pipeline, and earnings, such as early releases from EPM and refund bridges from LOVE. The manager will also consider evidence integrity, including prices with delayed timestamps and emitted bars, as well as collectors, including actual end dates and challenges versus content. Additionally, the manager will consider trade eligibility, including historical edge, such as train and holdout sets, costs, and censored trades, and payoff, such as defensible targets greater than or equal to 3R and half Kelly gap with a fund cap of $49.14. The manager will also consider the outer structure, including cash capture, such as working capital and payer manufacturing, and incentives, such as issuer optimism and shutdown pressure. The manager will read notes, then observations, then analyses and lessons. The manager notes that a paper with a return of 1.5R cannot justify a new target of 3R. The manager will review existing research and not conduct a new parameter search. The review is due on August 8 or 9, and there are no current holdings or queued orders according to the query.

The Catalyst fund is currently researching IONS, MIRM, and GIS, with a size of 0, as of September 10, 2026, at 19:30:25 UTC. The fund has noted the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. On September 9, 2026, Barclays maintained an overweight rating on Ionis Pharmaceuticals, but lowered its price target to $85. GIS had a conference on September 8, 2026, at 19:40 UTC, which has already passed. The fund will review earnings for GIS on September 23, 2026, and for EAT on October 28, 2026. The fund's baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5% and savings of $750m. The fund will review EAT's investor day on September 17, 2026, and earnings call on October 28, 2026. The fund will verify full pipelines and early news for all four companies.

The final handoff for EXTRA910 has begun, running from 18:28:48 to 18:34 UTC, with the finish phase starting at 18:31:50, well within the 37-minute allowance and 45-minute hard limit. There are no orders currently, and the fund's cash is at 49.14. Analyses 2278-2282 and the final strategy have been reviewed, along with observations 22879/81-84/88-91/96. The EPM, or Expected Profit Margin, was delayed at the 18:10 mark with a value of 3.795, an increase of 0.584322R, with a high of 3.82 and a low of 3.675, over 147 minutes, with no observed threshold touch. The frozen paper has an entry of 3.73, an ADR of 0.11124, a stop of 3.61876, and a target of 3.89686, with a close exit on September 14 unchanged. Current new trades require a minimum of 3R, half Kelly, and 3% normal or 5% convex risk, superseding the old convention of 1% and 1.5R, but there is no eligible edge. The paper target should not be widened to 4.06372, using only arithmetic. 208 and 209 remain armed at 19:40, with 168 paper exits and 193 TLX-CPI-ZUMZ retained, and 20 are not due, with no new monitor needed. Five jobs have been maintained, including 172 actual at 16:45, which resolves the lunch pending and IPHA ValueError, with hash not full content, and 132 and 17:01 and 67 complete at 17:15 and 17:01. The full SEC cash has been reconfirmed for LOVE, with an investment of -23.633m after a 21m refund, and the old guidance bridge and public call remain unread. The SRRK from August 21 explicitly allows for early approval through September 30, and the current RSS has no newer facility news, which is not proof of pending news. The TLX date from April 10 to September 11 has been reverified, with the latest RSS Ga at 68. The latest EPM feed from September 8 has no early results in bounded 3 items. Access gaps for M/MCFT/CAL and full SRRK replay have been deferred, with no renewed headline claims. There are no fresh backtests or simulations claimed, and the original 1928 and 1942 have been reviewed. There have been no unrelated fund actions.

The automated trading fund manager started a 37-minute plan at 18:28:48 UTC, with a hard stop at 45 minutes and a final 5 minutes reserved. Before this, the manager thought cash was likely the best option and set aside $349.01 for recovery. The manager decided to use existing recorded setups, rather than optimizing new screens. The manager considered several questions, including: 1. Was there an unexpected change? This included checking for early news from issuers and the latest feed, as well as FDA exposure, including decisions about TLX and SRRK facilities and pipelines. 2. What was the quality of the evidence? This included checking the paper path for delayed timestamps and gaps, as well as the integrity of the collector, including actual ends and source errors. 3. Was the trade justified? This included looking at existing tests, including train and holdout tests, and costs and uncertainty, as well as the potential payoff, including target returns and gap and cash caps. 4. What was the structure and context? This included looking at company cash capture, including LOVE refunds and recurring revenue, and FDA approval versus launch and cash, as well as prior losses, including early unrelated pipeline losses and fractional exit delays. The current instructions supersede old conventions of 1% and 1.5R per quarter Kelly for new trades, but frozen papers remain unchanged. No supported size was established by making the rules looser. The next run is at 19:40, and the manager will preserve $208 and $209.

The Catalyst fund, which is for research only and has a size of 0, was updated on September 10, 2026, at 17:15:53 UTC. The fund manager reviewed the following SEC filings: CHWY on September 9, 2026, ASO on September 9, 2026, and LOVE on September 10, 2026. The manager also reviewed an 8-K filing from SFIX on July 28, 2026. Additionally, the manager looked at news releases from SAIL, KFY, and LOVE, which were published on September 9 and 10, 2026. The manager also checked the FDA website for information on GRAL, which has a panel meeting scheduled for September 23, 2026. The manager noted that SEC filings may lag behind news and that reviews are scheduled for September 9, 12:30, for new morning results, September 10, 12:30, for LOVE, and September 24, 12:30, for SFIX, after the September 23 AMC. The manager also noted that the GRAL panel meeting on September 23 is not for approval. The manager emphasized the importance of strong cash positions, which should be recorded and validated, while weak or early positions should be cashed out and reverified. No automatic orders were placed.

The fund is called Catalyst Research and it has no size. The current time is 2026-09-10T17:01:23.707009+00:00 in UTC time, which is a way to show the time in a standard format. There are some updates about the stocks SRRK, SCHL, and PRAX. SRRK is Scholar Rock, a company that received FDA Fast Track Designation, which means the FDA will review their application quickly. They also presented at an investor conference and provided an update on their product apitegromab. SCHL is Scholastic Corporation, which announced the date for their first quarter fiscal 2027 report. PRAX is Praxis Precision Medicines, Inc., which announced inducement grants. There is also a link to an SEC filing for SRRK from 2026-08-06. The fund will review SRRK on September 9, 10, and 29 before September 30. SCHL will be reviewed on September 25 after their report is released on September 24. PRAX will be reviewed on December 27, replacing the previous review on September 27. The fund uses a system where if the data is favorable, it will be recorded and validated independently. If the data is adverse, delayed, or absent, the fund will revert to cash and reverify. The fund does not automatically enter trades and the reminders are not exact execution times. The sources and full branches are in the journal. The fund has 3 SRRK, 1 SCHL, and 1 PRAX, and 1 SEC filing, but this is not an exhaustive list.

The fund is called Catalyst Research and it is for research purposes only. The size of the fund is 0 and the time of the update is 2026-09-10T16:45:44.289654+00:00. There are several news updates from various companies, including Telix Pharma on Thursday, September 10, 2026, Mission Produce on Tuesday, September 8, 2026, ABM on Tuesday, September 8, 2026, Roivant on Tuesday, September 8, 2026, and Evolution Petroleum on Tuesday, September 8, 2026. Additionally, there are financial reports from UNFI on September 8, 2026, DRI on July 24, 2026, PPIH on September 9, 2026, MRK on August 7, 2026, and WLTH on September 9, 2026. There is also a 6-K report from IPHA on September 10, 2026. The HTTP status codes for KGF, ASKUL, IPHAnews, and SOBI are all 200, with corresponding hashes. The research notes end with the instruction to preserve certain monitors and not to place any orders. A decision has been made regarding IPHA, with a condition related to Sobi receipt and Q1-2028.

A previous note about the LUNCH910 EPM collector recipe was not saved because it was too long. This note provides the recipe instead. The new collector was not scheduled for job 422 with a five job cap, so the existing five jobs will be kept and a manual bar check will be done at 19:40 on August 19. A test of the local command bash /tmp/codex-run-iWGC3U/epm_collector.sh was successful, returning exit 0 at 16:36:50. The portable method for collecting data is to use the GET request to $SITE_URL/data/stock-bars with an Authorization Bearer $DATA_TOKEN, querying for symbols EPM, a timeframe of 1 minute, a start time of 2026-09-10T13:30:00Z, and an end time of the current UTC time minus 20 minutes rounded down to the nearest minute, with a feed of sip, adjustment of all, and a limit of 10000. The request will timeout after 20 seconds and raise an HTTP error if there is one, and it requires non-empty bars for EPM and a null next_page_token. The source URL, UTC time, count, first and last timestamps, last close, minimum low, maximum high, sum of volume, and any low or high that meets certain conditions will be printed, along with a calculated mark R. If there is an error, it will be printed and the program will exit with a code of 1. The program will also exit without fetching data if the UTC time is greater than or equal to 2026-09-10T19:41. The test ran for 97 minutes until 16:16 and resulted in a last close of 3.8, a high of 3.805, a low of 3.675, a volume of 224696, and a calculated R of 0.629270, with no hits. This recipe is for evidence collection only and does not include trade logic. The full source and local raw data may not be preserved in the next environment, but the recipe provided here is sufficient. The final strategy is 2267 and observations 22870 and 22871 hold the actual test and capacity results.

A news scan found the headline about LUNCH910 final handoff: zero allocation, next monitors 208/209. The automated trading fund manager's notes for Run 16:30:57–~16:38 UTC, within the 32-minute plan and 45-minute hard limit, show that the finish phase began at 16:35. There were no proposals, and the fund retained 49.14% of its cash. The manager performed analyses, including 2261 technical, 2262 fundamental, 2263 statistical, 2264 simulation, and 2265 consequences analyses, plus a final strategy review and lessons 669–671. The EPM paper was updated at 16:15 with a value of C3.805+0.674218R, and again at 16:16 with a value of C3.8+0.629270R, with no emitted bar hit, and frozen values of 3.73, 0.11124, 3.61876, and 3.89686, and the September 14 close exit remained unchanged. The manager made observations, including 22852, 55, 57, 59, 66–70, and a capacity observation. The training was negative, with an N6CI cross of 0, and a stress RR of 1.08023, resulting in an allocation of 0. The LOVE 10Q H1 OCF had a loss of 23.633 million despite a 21 million refund, with an old EBITDA refund bridge of unknown status. The LOVE registration and SRRKJS shell were unread, with M/MCFT/CAL 403 source gaps explicitly preserved. The TLX April 10 original September 11 date was reverified, with the current decision not proven and pending. Issues 200 and 201 were resolved, with 208 and 209 having paper bars manual and issuer bridge/collectors at 19:40, and 20 armed with none due. The September 14 exit and 193 TLX/CPI/ZUMZ were preserved. Five jobs, 67, 75, 126, 132, and 172, were retained, with actual job 126 completed at 15:15, and job 172 receipt still unconfirmed at 16:37, with an IPHA news ValueError. The EPM script test passed, but the schedule was rejected due to a 422 five job cap, with no new job and a recipe in a prior note. There was no new strategy optimization, no fresh backtest, and no order, with historical SIP not NBBO. The monthly shortfall of 349.01 was excluded from sizing.

The process starts at 16:30:57 UTC and has a 32-minute time allowance, with a hard stop at 45 minutes and a final 5 minutes reserved. The initial step is to set aside the desire to recover $349.01 and ensure there is sufficient prior cash. The focus is on resolving existing frozen setups and making changes to the current primary setups, without screening for new ones. The question tree includes: 1. Checking for unexpected contamination, which includes checking early news from issuer RSS and corporate actions, and monitoring paper progress, including delayed SIP timestamps and frozen daily proxy without a retroactive 15-minute rule. 2. Reviewing morning disclosures, such as the LOVE guide bridge, including prior refund definition and public transcript reconciliation, and assessing SRRK/TLX risk, including public replay and manufacturing, and early FDA and whole pipeline information. 3. Determining if evidence supports capital, including frozen validation, such as train and holdout, costs, and uncertainty, and feasibility, including cash of $49.14 and 1% equity of $8.5099, and actual fresh quotes and whole lots. 4. Evaluating off-run coverage, including monitors, such as resolving 200 and 201 outcomes, and the next review at 19:40, and collectors, including actual END and latest timestamps, and failures distinct from no news. Lessons 657 through 659 apply to this process. No orders will be placed, and only CIO proposals will be considered.

The fund manager of the Catalyst fund is researching IONS, MIRM, and GIS, with a size of 0, as of September 10, 2026, at 15:15:54 UTC. The manager has found the following SEC filings: IONS on September 4, 2026, MIRM on September 8, 2026, GIS on July 1, 2026, and EAT on August 12, 2026. A news scan found the headline that Barclays maintains an overweight rating on Ionis Pharmaceuticals and lowers its price target to $85 on September 9, 2026. GIS had a conference on September 8, 2026, at 19:00 UTC, which has already passed. The manager notes that GIS will have earnings on September 23, 2026, at 13:00 UTC, with a Q&A session, but the exact time of the first release is unknown. The manager will review the earnings and verify the cash flow, with no automatic entry. The baseline for GIS is an EPS of $3.00-3.20 for FY27, with organic growth of -1.5% to +0.5%, and savings of $750 million. The manager also notes that EAT will have an investor day on September 17, 2026, and an earnings call on October 28, 2026, with a review at 16:30 UTC on both days. The manager will verify the first news and reverify the cash flow, with no automatic trade. The manager has chosen to review the earnings and investor day, but will not retune past tests. The manager will verify the full pipelines and early news for IONS, MIRM, GIS, and EAT.

A news scan found the headline of a trading fund manager's notes. The notes state that from 13:50:55 to approximately 13:58 UTC, within a 33-minute plan and 45-minute hard limit, the finish phase began at 13:56. There were no proposals, and all 49.14 fund cash was analyzed. The analyses included 2246 technical, 2247 statistical, 2248 fundamental, and 2249 consequences analyses, plus a final strategy and lessons 657-659. The actual EPM was delayed, with an SIP open of 3.73, ADR of 11124, stop at 3.61876, and target at 3.89686, with a paper exit on September 14 close and stress RR of 1.08023, but no order was placed. On September 10 at 16:30, a check of paper and early news was conducted, and on September 14, an exit was made. On September 16 at 16:30, a LOVE guide bridge, SRRK replay, and M-MCFT-CAL original 403 gaps were used. The notes also mention that 193 TLX, CPI, and ZUMZ were preserved on September 11. There were 20 armed and none overdue, 5 active jobs, and 0 live, pending, or closing jobs. The PPI actual for August was +0.4 month-over-month and 5.4 year-over-year, with a July revision from 0 to +0.1 verified from original archives. The LOVE open was 14.04 versus 16.03, which is a -12.4142% difference. The current SIP snapshot is 403, with delayed bars not being NBBO. The Q2 EBITDA explicit refund exclusion versus the old generic definition means a 17.28% nominal cut that is not fully organic, with a conditional 3.6 million restatement that is not exact. The public LOVE registration and SRRK JS shell contents were unread. The EPM prior backtest from 1928 training showed a -6.551% result, with all 12 being negative, and a holdout of 6 CI cross 0. The simulation from 1942 was unchanged and approved with a Kelly of 0. A correction was made to a stray 1930 typo, which was only in paper 1734. The files research.py, follow.py, and extra.py, along with raw sources and calc.json local, were used, with decisive inputs from August 26 to 33 persisted. There were no repeated tests or new strategy selections made during the trading run.